Last €54.14 EUR
Change Today -0.407 / -0.75%
Volume 17.0
AXS On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:29 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

abaxis inc (AXS) Snapshot

Open
€54.28
Previous Close
€54.55
Day High
€54.28
Day Low
€53.72
52 Week High
01/30/15 - €56.19
52 Week Low
03/26/14 - €26.51
Market Cap
1.2B
Average Volume 10 Days
14.6
EPS TTM
--
Shares Outstanding
22.5M
EX-Date
02/27/15
P/E TM
--
Dividend
€0.40
Dividend Yield
0.59%
Current Stock Chart for ABAXIS INC (AXS)

abaxis inc (AXS) Related Businessweek News

No Related Businessweek News Found

abaxis inc (AXS) Details

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo Xpress chemistry analyzers with blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. It also provides VetScan VS2, a chemistry, electrolyte, immunoassay, and blood gas analyzer delivering results from a sample of whole blood, serum, or plasma; VetScan HM5; and VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, the company offers VetScan VSpro that assists the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, disseminated intravascular coagulation evaluation, hepatic disease, monitoring therapy, and disease progression states; VetScan VSpro coagulation test to evaluate prothrombin and the activated partial thromboplastin times; VetScan VSpro fibrinogen test for in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; and i-STAT that delivers blood gas, electrolyte, chemistry, and hematology results. Further, it provides VetScan Canine Heartworm rapid test to detect dirofilaria immitis in canine whole blood, serum, or plasma; VetScan Canine Lyme rapid test to detect Borrelia burgdorferi in canine whole blood, serum, or plasma; Vetscan Canine Parvovirus rapid test to detect canine parvovirus antigen in feces; and VetScan Giardia rapid test to detect Giardia cyst antigens in canine feces, as well as veterinary reference laboratory diagnostic and consulting services. Abaxis, Inc. sells its products through direct sales force and independent distributors. The company was founded in 1989 and is headquartered in Union City, California.

520 Employees
Last Reported Date: 05/30/14
Founded in 1989

abaxis inc (AXS) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $478.1K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $258.5K
Chief Operations Officer
Total Annual Compensation: $258.5K
Chief Technology Officer
Total Annual Compensation: $258.5K
Compensation as of Fiscal Year 2014.

abaxis inc (AXS) Key Developments

Abaxis, Inc. Declares Third Quarter Cash Dividend, Payable on March 17, 2015; Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Abaxis, Inc. announced that its Board of Directors declared a quarterly cash dividend of $0.10 per common share to be paid on March 17, 2015, to all shareholders of record as of the close of business on March 3, 2015. The company announced unaudited consolidated earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported revenues of $59.5 million, as compared with revenues of $40.8 million for the comparable period last year, an increase of 46%. The company reported net income of $5.9 million compared to $3.2 million for the fiscal quarter ended December 31, 2013. The company reported diluted net income per share of $0.26 compared to $0.14 per share for the same period last year. Income from operations was $9,156,000 against $4,623,000 a year ago. Income before income tax was $8,959,000 against $4,858,000 a year ago. For the nine-months, the company reported revenues of $160.9 million as compared with revenues of $129.8 million for the comparable period last year, an increase of 24%. The company reported net income of $16.0 million compared to $10.4 million for the same period last year. The company reported diluted net income per share of $0.70 for the nine-month period ended December 31, 2014, compared to $0.46 per share for the same period last year. Income from operations was $25,522,000 against $14,958,000 a year ago. Income before income tax Was $24,927,000 against $16,104,000 a year ago.

Abaxis, Inc. Announces U.S. Department of Agriculture Approval of VetScan FeLV-FIV Rapid Test Kit

Abaxis, Inc. announced that the Center for Veterinary Biologicals of the U.S. Department of Agriculture (USDA) has approved its VetScan FeLV-FIV Rapid Test Kit for the detection of FeLV antigen and FIV antibodies from feline blood samples. Feline Leukemia virus (FeLV) and the feline immunodefiency virus (FIV) are retroviruses found in cats, and are among the most common infectious diseases in this species. FeLV-FIV testing is one of the most common tests performed by veterinarians treating feline patients, and Abaxis is proud to offer another high quality, cost-effective test to the veterinary market.

Abaxis, Inc. to Report Q3, 2015 Results on Jan 29, 2015

Abaxis, Inc. announced that they will report Q3, 2015 results at 5:00 PM, Eastern Standard Time on Jan 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AXS:GR €54.14 EUR -0.407

AXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $119.00 USD +1.07
Corgenix Medical Corp $0.27 USD +0.0062
Heska Corp $21.67 USD +0.37
Millennium Healthcare Inc $0.07 USD -0.0198
PetMed Express Inc $15.48 USD -0.01
View Industry Companies
 

Industry Analysis

AXS

Industry Average

Valuation AXS Industry Range
Price/Earnings 71.2x
Price/Sales 6.9x
Price/Book 6.7x
Price/Cash Flow 70.7x
TEV/Sales 6.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABAXIS INC, please visit www.abaxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.